JP2018520638A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520638A5 JP2018520638A5 JP2017555779A JP2017555779A JP2018520638A5 JP 2018520638 A5 JP2018520638 A5 JP 2018520638A5 JP 2017555779 A JP2017555779 A JP 2017555779A JP 2017555779 A JP2017555779 A JP 2017555779A JP 2018520638 A5 JP2018520638 A5 JP 2018520638A5
- Authority
- JP
- Japan
- Prior art keywords
- percent
- agent
- cells
- less
- aliquot
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 136
- 238000000034 method Methods 0.000 claims description 124
- 239000003795 chemical substances by application Substances 0.000 claims description 104
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 55
- 238000012360 testing method Methods 0.000 claims description 44
- 230000037452 priming Effects 0.000 claims description 39
- 230000002438 mitochondrial effect Effects 0.000 claims description 21
- 241001465754 Metazoa Species 0.000 claims description 14
- 230000000861 pro-apoptotic effect Effects 0.000 claims description 14
- FYNNIUVBDKICAX-UHFFFAOYSA-M 1,1',3,3'-tetraethyl-5,5',6,6'-tetrachloroimidacarbocyanine iodide Chemical group [I-].CCN1C2=CC(Cl)=C(Cl)C=C2N(CC)C1=CC=CC1=[N+](CC)C2=CC(Cl)=C(Cl)C=C2N1CC FYNNIUVBDKICAX-UHFFFAOYSA-M 0.000 claims description 12
- 101150082208 DIABLO gene Proteins 0.000 claims description 12
- 239000002246 antineoplastic agent Substances 0.000 claims description 12
- 238000001727 in vivo Methods 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 231100000331 toxic Toxicity 0.000 claims description 8
- 230000002588 toxic effect Effects 0.000 claims description 8
- 231100000820 toxicity test Toxicity 0.000 claims description 8
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 claims description 7
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 claims description 7
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 claims description 7
- 231100000580 in vitro toxicity testing Toxicity 0.000 claims description 7
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 7
- 229930182490 saponin Natural products 0.000 claims description 7
- 150000007949 saponins Chemical class 0.000 claims description 7
- RZCJYMOBWVJQGV-UHFFFAOYSA-N 2-naphthyloxyacetic acid Chemical compound C1=CC=CC2=CC(OCC(=O)O)=CC=C21 RZCJYMOBWVJQGV-UHFFFAOYSA-N 0.000 claims description 6
- 102000003829 Adenylate kinase 2 Human genes 0.000 claims description 6
- 108090000115 Adenylate kinase 2 Proteins 0.000 claims description 6
- 102100030497 Cytochrome c Human genes 0.000 claims description 6
- 108010075031 Cytochromes c Proteins 0.000 claims description 6
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 101100232163 Mus musculus Htra2 gene Proteins 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 239000000443 aerosol Substances 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 230000006907 apoptotic process Effects 0.000 claims description 6
- 239000012867 bioactive agent Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 230000005670 electromagnetic radiation Effects 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 6
- 239000003102 growth factor Substances 0.000 claims description 6
- 239000005556 hormone Substances 0.000 claims description 6
- 229940088597 hormone Drugs 0.000 claims description 6
- 239000000411 inducer Substances 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- 238000004020 luminiscence type Methods 0.000 claims description 6
- 230000014759 maintenance of location Effects 0.000 claims description 6
- FNEZBBILNYNQGC-UHFFFAOYSA-N methyl 2-(3,6-diamino-9h-xanthen-9-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1C2=CC=C(N)C=C2OC2=CC(N)=CC=C21 FNEZBBILNYNQGC-UHFFFAOYSA-N 0.000 claims description 6
- 231100001143 noxa Toxicity 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 6
- 231100000419 toxicity Toxicity 0.000 claims description 6
- 230000001988 toxicity Effects 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 4
- 229940000425 combination drug Drugs 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 238000011887 Necropsy Methods 0.000 claims description 2
- 241000283984 Rodentia Species 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 230000008823 permeabilization Effects 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 238000003307 slaughter Methods 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 231100000041 toxicology testing Toxicity 0.000 claims 3
- 239000008191 permeabilizing agent Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562153475P | 2015-04-27 | 2015-04-27 | |
| US62/153,475 | 2015-04-27 | ||
| PCT/US2016/029510 WO2016176299A1 (en) | 2015-04-27 | 2016-04-27 | Compositions and methods for assessing toxicity using dynamic bh3 profiling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020200805A Division JP2021036915A (ja) | 2015-04-27 | 2020-12-03 | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520638A JP2018520638A (ja) | 2018-08-02 |
| JP2018520638A5 true JP2018520638A5 (enExample) | 2019-07-04 |
| JP6814745B2 JP6814745B2 (ja) | 2021-01-20 |
Family
ID=57198812
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555779A Active JP6814745B2 (ja) | 2015-04-27 | 2016-04-27 | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 |
| JP2017555780A Active JP6802185B2 (ja) | 2015-04-27 | 2016-04-27 | ハイスループットｂｈ３プロファイリング：少量の細胞でのｂｈ３プロファイルのための迅速かつ拡大縮小可能な技術 |
| JP2020200805A Withdrawn JP2021036915A (ja) | 2015-04-27 | 2020-12-03 | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555780A Active JP6802185B2 (ja) | 2015-04-27 | 2016-04-27 | ハイスループットｂｈ３プロファイリング：少量の細胞でのｂｈ３プロファイルのための迅速かつ拡大縮小可能な技術 |
| JP2020200805A Withdrawn JP2021036915A (ja) | 2015-04-27 | 2020-12-03 | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20180120297A1 (enExample) |
| EP (2) | EP3289094B1 (enExample) |
| JP (3) | JP6814745B2 (enExample) |
| AU (2) | AU2016255749B2 (enExample) |
| CA (2) | CA2983024A1 (enExample) |
| WO (2) | WO2016176288A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022580A2 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
| US8221966B2 (en) | 2006-03-31 | 2012-07-17 | Dana Farber Cancer Institute | Methods of determining cellular chemosensitivity |
| WO2014047342A1 (en) | 2012-09-19 | 2014-03-27 | Dana-Farber Cancer Institute, Inc. | Dynamic bh3 profiling |
| JP6663852B2 (ja) | 2013-09-19 | 2020-03-13 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｂｈ３プロファイリングの方法 |
| HK1247250A1 (zh) | 2015-01-12 | 2018-09-21 | Eutropics Pharmaceuticals, Inc. | 用於指导癌症治疗的内容相关的诊断测试 |
| WO2016149613A2 (en) | 2015-03-18 | 2016-09-22 | Massachusetts Institute Of Technology | Selective mcl-1 binding peptides |
| JP6851978B2 (ja) | 2015-04-20 | 2021-03-31 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | ミトコンドリアプロファイリングによるアルボシジブ応答の予測 |
| EP3289094B1 (en) | 2015-04-27 | 2024-06-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for assessing toxicity using dynamic bh3 profiling |
| JP6510075B2 (ja) | 2015-05-18 | 2019-05-08 | トレロ ファーマシューティカルズ， インコーポレイテッド | バイオアベイラビリティが高いアルボシジブプロドラッグ |
| EP3331510A4 (en) | 2015-08-03 | 2019-04-03 | Tolero Pharmaceuticals, Inc. | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
| WO2018017922A2 (en) | 2016-07-22 | 2018-01-25 | Massachusetts Institute Of Technology | Selective bfl-1 peptides |
| US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| CA3047557A1 (en) * | 2016-12-19 | 2018-06-28 | Tolero Pharmaceuticals, Inc. | Profiling peptides and methods for sensitivity profiling |
| WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
| EP3852783A1 (en) * | 2018-09-17 | 2021-07-28 | Massachusetts Institute of Technology | Peptides selective for bcl-2 family proteins |
| US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| WO2020176689A1 (en) * | 2019-02-26 | 2020-09-03 | Dana-Farber Cancer Institute, Inc. | Live cell imaging dynamic bh3 profiling |
| US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5674980A (en) | 1989-12-21 | 1997-10-07 | Biogen Inc | Fusion protein comprising tat-derived transport moiety |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| AU705563B2 (en) | 1995-07-28 | 1999-05-27 | Marie Curie Cancer Care | Transport proteins and their uses |
| JP3295431B2 (ja) * | 1995-10-24 | 2002-06-24 | サングスタット メディカル コーポレイション | 抗アルファ−ガラクトシルスクリーニング技術 |
| US5965703A (en) | 1996-09-20 | 1999-10-12 | Idun Pharmaceuticals | Human bad polypeptides, encoding nucleic acids and methods of use |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| WO1999014321A1 (en) | 1997-09-17 | 1999-03-25 | The Walter And Eliza Hall Institute Of Medical Research | Novel therapeutic molecules |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| EP1210098A1 (en) | 1999-04-07 | 2002-06-05 | Thomas Jefferson University | Enhancement of peptide cellular uptake |
| WO2001012661A2 (en) | 1999-08-16 | 2001-02-22 | The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healthand Human Services, The National Institutes Of Health | RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS |
| WO2002020568A2 (en) | 2000-09-06 | 2002-03-14 | Abbott Laboratories | Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins |
| US20020115613A1 (en) | 2001-02-16 | 2002-08-22 | Kumar M. Vijay | Treatment of prostate cancer |
| WO2003040168A2 (en) * | 2001-11-06 | 2003-05-15 | Enanta Pharmaceuticals, Inc. | Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype |
| JP2005518393A (ja) * | 2001-12-21 | 2005-06-23 | アリアス リサーチ、インコーポレイテッド | 個別化抗癌抗体 |
| WO2004022580A2 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
| US20070032417A1 (en) | 2002-12-24 | 2007-02-08 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
| WO2004083405A2 (en) | 2003-03-19 | 2004-09-30 | Alfa Wassermann, Inc. | Separation and accumulation of subcellular components, and proteins derived therefrom |
| PT2332968T (pt) | 2003-11-05 | 2016-08-17 | Harvard College | Péptidos alfa-helicoidais adequados para a activação ou inibição da morte celular |
| WO2006069186A2 (en) | 2004-12-22 | 2006-06-29 | The Ohio State Research Foundation | Small molecule bcl-xl/bcl-2 binding inhibitors |
| JP2005130867A (ja) | 2005-02-16 | 2005-05-26 | Mitokor | ミトコンドリア内カルシウムを使用するスクリーニングアッセイ |
| WO2006099667A1 (en) | 2005-03-21 | 2006-09-28 | The Walter And Eliza Hall Institute Of Medical Research | Prophylactic and therapeutic agents and uses therefor |
| WO2007016254A2 (en) | 2005-07-27 | 2007-02-08 | The Board Of Trustees Of The University Of Arkansas | Antineoplastic activities of ellipticine and its derivatives |
| US8221966B2 (en) * | 2006-03-31 | 2012-07-17 | Dana Farber Cancer Institute | Methods of determining cellular chemosensitivity |
| US8518635B2 (en) | 2006-06-12 | 2013-08-27 | The J. David Gladstone Institutes | Regulation of protein activity by reversible acetylation |
| KR100786759B1 (ko) | 2006-07-07 | 2007-12-18 | 김현기 | Ｈｃｃｒ-1을 포함하는 유방암 예후 마커 및 비만 유도조성물 |
| US9360473B2 (en) | 2006-08-16 | 2016-06-07 | Eutropics Pharmaceuticals, Inc. | Assay system to identify therapeutic agents |
| WO2008152405A2 (en) | 2007-06-15 | 2008-12-18 | The Queen's University Of Belfast | Protein complexes comprising bh3 peptides and voltage dependent anion channel (vdac) peptides as well as uses thereof for the treatment of proliferative diseases |
| KR20100074177A (ko) | 2007-09-10 | 2010-07-01 | 유니버시티 오브 매사추세츠 | 미토콘드리아-표적화된 항-종양 물질 |
| CA2700925C (en) * | 2007-09-26 | 2016-08-23 | Dana Farber Cancer Institute | Methods and compositions for modulating bcl-2 family polypeptides |
| JP2009240173A (ja) | 2008-03-28 | 2009-10-22 | Univ Of Tokushima | パーキン蛋白の新規糖化因子 |
| EA026732B1 (ru) | 2009-06-11 | 2017-05-31 | Минерва Байотекнолоджиз Корпорейшн | Способы культивирования стволовых клеток и клеток-предшественников |
| WO2010147961A1 (en) | 2009-06-15 | 2010-12-23 | Precision Therapeutics, Inc. | Methods and markers for predicting responses to chemotherapy |
| US20130122492A1 (en) * | 2011-11-14 | 2013-05-16 | Kellbenx Inc. | Detection, isolation and analysis of rare cells in biological fluids |
| CN107315088A (zh) * | 2012-05-10 | 2017-11-03 | 尤特罗皮克斯制药股份有限公司 | 对癌症的代理功能性诊断测试 |
| US20150322479A1 (en) | 2012-06-20 | 2015-11-12 | Cytospan Technologies Corporation | Apparatus and method for quantification of replicative lifespan and observation of senescene |
| WO2014047342A1 (en) | 2012-09-19 | 2014-03-27 | Dana-Farber Cancer Institute, Inc. | Dynamic bh3 profiling |
| JP6327662B2 (ja) | 2012-09-26 | 2018-05-23 | 学校法人藤田学園 | 細胞表面タンパクを抗原とする抗体を測定する方法 |
| JP2016526892A (ja) | 2013-07-18 | 2016-09-08 | ユートロピクス ファーマシューティカルズ， インコーポレイテッド | 示差的ｂｈ３ミトコンドリアプロファイリング |
| JP6663852B2 (ja) | 2013-09-19 | 2020-03-13 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｂｈ３プロファイリングの方法 |
| EP3289094B1 (en) | 2015-04-27 | 2024-06-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for assessing toxicity using dynamic bh3 profiling |
| WO2017007858A1 (en) | 2015-07-06 | 2017-01-12 | Whitehead Institute For Biomedical Research | Methods and compositions relating to proteasome inhibitor resistance |
| WO2020176689A1 (en) | 2019-02-26 | 2020-09-03 | Dana-Farber Cancer Institute, Inc. | Live cell imaging dynamic bh3 profiling |
-
2016
- 2016-04-27 EP EP16787045.0A patent/EP3289094B1/en active Active
- 2016-04-27 WO PCT/US2016/029495 patent/WO2016176288A1/en not_active Ceased
- 2016-04-27 JP JP2017555779A patent/JP6814745B2/ja active Active
- 2016-04-27 CA CA2983024A patent/CA2983024A1/en active Pending
- 2016-04-27 JP JP2017555780A patent/JP6802185B2/ja active Active
- 2016-04-27 US US15/569,851 patent/US20180120297A1/en not_active Abandoned
- 2016-04-27 AU AU2016255749A patent/AU2016255749B2/en active Active
- 2016-04-27 WO PCT/US2016/029510 patent/WO2016176299A1/en not_active Ceased
- 2016-04-27 AU AU2016253957A patent/AU2016253957C1/en active Active
- 2016-04-27 US US15/568,994 patent/US10761086B2/en active Active
- 2016-04-27 EP EP16787039.3A patent/EP3288964B1/en active Active
- 2016-04-27 CA CA2983022A patent/CA2983022C/en active Active
-
2020
- 2020-07-27 US US16/939,736 patent/US11867688B2/en active Active
- 2020-12-03 JP JP2020200805A patent/JP2021036915A/ja not_active Withdrawn
-
2021
- 2021-02-26 US US17/186,344 patent/US20210255167A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520638A5 (enExample) | ||
| JP2021036915A5 (enExample) | ||
| Luan et al. | NOD-like receptor protein 3 inflammasome-dependent IL-1β accelerated ConA-induced hepatitis | |
| Stahlhut et al. | Identification of filamin as a novel ligand for caveolin-1: evidence for the organization of caveolin-1–associated membrane domains by the actin cytoskeleton | |
| AU2016255749B2 (en) | Compositions and methods for assessing toxicity using Dynamic BH3 profiling | |
| US10272114B1 (en) | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | |
| US20180021323A1 (en) | Flip - a selective molecular target of senescent cells | |
| TW201345544A (zh) | Ｈｌａ-ａ＊１１０１限制性ｗｔ１胜肽之用途 | |
| WO2016138420A1 (en) | Targeted transplantation of mitochondria to hepatocytes | |
| King | Dyneins: dynein mechanics, dysfunction, and disease | |
| Noguchi et al. | Effects of lyophilization of arginine-rich cell-penetrating peptide-modified extracellular vesicles on intracellular delivery | |
| Malécot et al. | Proteomic study of the effects of microcystin-LR on organelle and membrane proteins in medaka fish liver | |
| Balbi et al. | Message in a bottle: upgrading cardiac repair into rejuvenation | |
| Li et al. | Proteomic analysis of extracellular vesicles released from heat-stroked hepatocytes reveals promotion of programmed cell death pathway | |
| Shakib et al. | Proteomics profiling of nuclear proteins for kidney fibroblasts suggests hypoxia, meiosis, and cancer may meet in the nucleus | |
| ES2891081T3 (es) | Modificadores de la respuesta de células T citotóxicas | |
| Wong et al. | The therapeutic anticancer potential of marine-derived bioactive peptides: a highlight on pardaxin | |
| Bansal et al. | Discovery and characterization of a potent antifungal peptide through one-bead, one-compound combinatorial library screening | |
| US10597426B2 (en) | Polypeptide compound and preparation method and use thereof | |
| Zheng et al. | Cofactor-free detection of phosphatidylserine with cyclic peptides mimicking lactadherin | |
| CN105504015B (zh) | 一种mhc-i类限制性抗肿瘤ctl表位肽 | |
| Zhang et al. | Plasma metabolites-based design of long-acting peptides and their anticancer evaluation | |
| Schumacher et al. | Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L27Melan-A/MART-126–35 peptide encapsulated into virosomes in vitro | |
| CN107703109B (zh) | 二维硫化钼多肽复合材料及其在靶向cd47癌症标记中的应用 | |
| CN105524141B (zh) | 一种FAPa激活式肿瘤诊断多肽磁珠复合物的制备与应用 |